- The disease
- Obstructive sleep apnea is a condition in which the upper airway repeatedly collapses during sleep, causing breathing interruptions. It is commonly measured using the apnea-hypopnea index (AHI), which counts the number of breathing disruptions per hour of sleep. OSA is associated with daytime sleepiness, cardiovascular risk, and reduced quality of life. It affects a large proportion of adults globally, though prevalence estimates vary by diagnostic threshold and population studied.
- What the asset is trying to do
- SomnoDent Flex is a custom-fitted, two-piece oral appliance worn during sleep. It works by repositioning the lower jaw (mandible) slightly forward, which mechanically holds the upper airway open and reduces airway collapse. This approach, known as mandibular repositioning appliance (MRA) therapy, differs from continuous positive airway pressure (CPAP) therapy, which uses an air pump and mask to keep the airway open pneumatically. The SomnoDent device does not require a power source or mask.
- What the trial is measuring, and why it matters
- The completed trial registered as NCT01588275 compared MRA therapy (SomnoDent) against CPAP therapy in patients with moderate obstructive sleep apnea (per ClinicalTrials.gov NCT01588275). The trial enrolled a target of 86 participants and reached primary completion on 2017-12-31 (per ClinicalTrials.gov NCT01588275). Typical endpoints in MRA versus CPAP studies include changes in AHI, oxygen desaturation index, and patient-reported outcomes such as sleepiness scores, though the specific primary endpoint for this trial is .
- Efficacy benchmarks in this setting
- In the context of OSA device therapy, CPAP is the established standard of care and has demonstrated mean AHI reductions of approximately 75-85% in controlled settings, though this figure varies across studies and patient populations (Epstein et al, Journal of Clinical Sleep Medicine 2009). MRA devices as a class have shown mean AHI reductions of roughly 50% in meta-analyses of randomised trials, with patient adherence generally reported to be higher than for CPAP (Sharples et al, Health Technology Assessment 2014). Figures from early or single-arm studies of any individual device, including SomnoDent Flex, are not statistically comparable to these aggregate benchmarks due to differences in patient selection, AHI thresholds, and follow-up duration.
- Commercial context
- SomnoDent Flex is a marketed, commercially available oral appliance for OSA; it is not an investigational product. The device is sold through dental and sleep clinic channels in multiple countries including Australia, the United States, and Europe, though the specific list of regulatory approvals by jurisdiction is . SomnoMed (ASX: SOM) lists SomnoDent as its primary commercial product. No recent partnership or licensing deal terms have been disclosed in the announcements provided.